Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR1801 injection combined with human rabies vaccine in healthy volunteers
ChiCTR2100050771Phase 2Recruiting
- Sponsor
- Huashan Hospital
- Start
- Sep 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of silevimig in rabies (4 arms), sponsored by Huashan Hospital. Primary endpoint: Safety evaluation indicators. Started Sep 2021; status: recruiting.
02
Drugs
silevimig
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2100050771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050771.